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Liver disease is one of the leading causes of death worldwide1. Cirrhosis patients display 
an increased predisposition to and mortality from infection due to multimodal defects in 
the innate immune system2-4, however the causative mechanism has remained elusive. 
We present evidence that the cyclooxygenase (COX)-derived eicosanoid prostaglandin 
E2 (PGE2) drives cirrhosis-associated immunosuppression. Elevated circulating 
concentrations (>7x healthy volunteers) of PGE2 were observed in acutely 
decompensated (AD) patients. Plasma from these and end-stage liver disease (ESLD) 
patients suppressed macrophage pro-inflammatory cytokine secretion and bacterial 
killing in-vitro in a PGE2-E prostanoid receptor 2 (EP2) dependent manner, effects not 
replicated with plasma from stable cirrhotics (Child score A). Albumin, which reduces 
PGE2 bioavailability, was decreased in the AD/ESLD population (<30mg/dL) and 
appears to play a key role in modulating PGE2-mediated immune dysfunction. In vivo 
administration of human albumin solution (median 200ml of 20% HAS) to these 
patients improved the immunosuppressive burden in vitro. Two murine models of liver 
injury (bile duct ligation [BDL] and carbon tetrachloride [CCL4]) also exhibited 
elevated PGE2, reduced circulating albumin concentration and EP-2 mediated 
immunosuppression. Treatment with COX inhibitors or albumin restored immune 
competence and survival following infection. PGE2 suppression via stratified, targeted 
HAS infusions may represent a new immune restorative treatment paradigm for AD 
and ESLD inpatients. 
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The prevalence of liver disease is predicted to rise dramatically secondary to the global trends 
of obesity, higher alcohol consumption and rising hepatitis C virus transmission1. Infection 
represents a key cause of early death in this population, precipitating 50% of hospital 
admissions, with a further 15-35% developing nosocomial infections as inpatients5. 
Secondary sepsis and requirement for multi-organ support in intensive care is associated with 
65-90% mortality6. The dysfunction of both neutrophils and monocytes in cirrhosis has long 
been recognised to underlie this and the presence of an inhibitory humoral mediator 
speculated upon, yet not definitively identified7-9.  
 
Cirrhosis patients are markedly heterogeneous, with critical variance in aetiology and disease 
stage. Susceptibility to infection, reflecting immune dysfunction is highest in AD patients and 
lowest in stable cirrhosis10. Decompensated cirrhosis patients present with hepatic 
encephalopathy, ascites, variceal bleeding, alcoholic hepatitis and hyperbilirubinaemia. AD is 
defined by the acute development of one or more of these complications and includes acute 
on chronic liver failure (AoCLF4). Immunomodulatory therapy to both prevent and treat 
infections in the most vulnerable groups could reduce early mortality and thus reduce the 
health-economic burden of liver cirrhosis in the twenty-first century. 
 
Inflammation-driven COX-derived lipid mediators exert diverse effects on the innate immune 
system that could explain increased infective susceptibility in cirrhosis patients11-14. In 
particular PGE2 has widespread immunomodulatory roles dependent on its site of action and 
formation; being shown to be a key mediator of myeloid-derived cell dysfunction inhibiting 
NADPH oxidase-mediated bacterial killing15,16 via up-regulation of cAMP and inhibition of 
FcγR-mediated phagocytosis17,18. 
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Using electrospray ionization liquid chromatography tandem mass spectrometry (ESI/LC-
MS) to analyze AD patient plasma (day 1-2 of hospital admission) we demonstrated 
significantly elevated PGE2, PGF2α, 5- and 15-HETE compared to healthy volunteer (HV) 
plasma but not TxB2, 9-HODE, 12-HETE and 13-HODE (Fig. 1a and Supplementary Fig. 
1a-g). Of these, only PGE2 dampened TNFα release from LPS-stimulated human monocyte-
derived macrophages (MDM) at the concentrations observed (0.1ng/ml) (Fig. 1b). LPS-
stimulated MDM TNFα release was significantly decreased by incubation with culture media 
supplemented with 25% (vol./vol.) plasma from AD patients (Supplementary Table 1 for 
clinical characteristics) as opposed to HV plasma, an effect reversed by the addition of the EP 
1-3/D-prostanoid (DP) 1 receptor antagonist AH6809 (50μM (Fig. 1c). Macrophages were 
also incubated with Escherichia coli (clinical isolate). Compared to macrophages treated with 
HV plasma, those incubated with AD plasma exhibited reduced bacterial killing, an effect 
again reversed by pretreatment with AH6809 (50μM) (Fig. 1d). AH6809 had no direct 
bactericidal effect while cell viability was unaffected by AD/HV plasma.  
 
Plasma from AD patients showed persistent PGE2-mediated immunosuppression up to day 
six post-admission, able to reduce MDM TNFα and elevate IL-10 production (Fig. 1e,f). 
Importantly, although ~60% of day 1 AD plasma samples induced this immunosuppressive 
cytokine pattern (Fig. 1c), all patients’ plasma sampled from days 2-6 did in a PGE2-
dependent manner (Fig. 1e,f). PGE2 also mediated immunosuppression in ESLD patients 
with plasma from ESLD patients taken 24 weeks apart significantly impairing macrophage 
TNFα synthesis, an effect blocked by AH6809  (Fig. 2a). In contrast, samples from Child 
score A cirrhosis or non-cirrhotic liver disease outpatients had no effect on macrophage 
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function (Fig. 2b).  PGE2 levels were twice healthy volunteer levels in Child score A as 
opposed to 7-fold higher in AD (Fig. 1a and Supplementary Table 2). 
 
rtPCR revealed increased expression of COX 2 (p<0.00001), not COX 1 in peripheral blood 
mononuclear cells of AD patients compared to healthy volunteers (n=5/group, Fig. 2c). 
Immunohistochemical analysis of all organs from a murine model of cirrhosis (CCL4, which 
induces elevated PGE2, Fig. 2d) demonstrated up-regulation of COX 2 in Kupffer cells and 
alveolar macrophages compared to shams but not other organs (Fig. 2e and f) suggesting 
these three cell types as the likely sources of PGE2. 
 
We discovered that inhibiting PGE2 increased bacterial killing and restored survival in two 
animal models of liver injury. Although an imperfect experimental model, BDL mice do 
exhibit certain similarities to AD patients (e.g. high bilirubin and low albumin, 
(Supplementary Table 3) and were found to have >5-fold elevated PGE2 concentrations 
(Fig. 2d) but not other eicosanoids (Supplementary Fig. 2a-p). As in humans, BDL plasma 
suppressed macrophage TNF and increased IL-10 (Fig. 3a and Supplementary Fig. 3a,b) 
without affecting macrophage viability. This was prevented by pretreatment of the mice with 
the non-selective COX inhibitor indomethacin but not baicalein (12-lipoxygenase inhibitor) 
or SKF525A (p450 inhibitor) or if BDL plasma was heat-treated (protein denatured). Again, 
as in humans, immunosuppression was demonstrated to be mediated via a PGE2-E prostanoid 
receptor 2 (EP2) dependent mechanism (Supplementary Fig. 3c-i).  Experiments using 
CCL4 treated mice showed similar findings with significantly elevated PGE2 (Fig. 3b) and 
PGD2 but not other eicosanoids (Supplementary Fig. 4a-p). BDL mice were injected with 
live Group B streptococcus (GBS, NCTC10/84, serotype V). Consistent with 
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immunosuppression, bacteria were significantly elevated in BDL blood compared to shams 
(Fig. 3c,d). Treating BDL mice with indomethacin intraperitonealy (i.p.) or intravenously 
(inhibiting PGE2 concentration by >80%) 1h before GBS administration restored bacterial 
killing to sham levels (Fig. 3c,d). Indomethacin also improved survival following GBS 
challenge in BDL mice to that of shams (Fig. 3e). In the lung PGE2 protects against fibrosis
19 
and therefore reducing levels may worsen liver fibrosis. However histological analysis with 
H&E and Masson trichrom staining showed no difference in livers from celecoxib (selective 
COX 2 inhibitor) and non-celecoxib treated CCL4 mice (Fig. 3f,g).  
 
Correlating levels of TNF from macrophages incubated in the presence of AD plasma with 
corresponding plasma PGE2 levels surprisingly resulted in a modest r
2 of only 0.41 
(p=0.085). Albumin, hepatically synthesized and frequently reduced in liver disease, is 
known to bind A- and E-type PGs at the ligand-binding site I in subdomain 2A20. We 
postulated that immunosuppression might be a consequence of the bioavailability of PGE2 
determined by blood albumin concentration. Expressing AD plasma PGE2 levels according to 
corresponding albumin levels and then correlating these values with TNF synthesis resulted 
in a superior r2 value, 0.72 (p=0.0076) (Fig. 4a). Adding albumin to AD plasma in order to 
restore levels to 40mg/dl (equivalent to HV) reversed AD plasma induced suppression of 
TNFα generation (Fig. 4b). Furthermore supplementing culture media with 40mg/dl of 
albumin impaired PGE2 inhibition of TNFα release (Fig. 4c).  
 
To further define this relationship AD plasma samples that dampened TNF below the 
lowest TNF exerted by healthy plasma (Fig. 4a) were arbitrarily grouped into ADMIS (AD 
plasma from most immunosuppressed) and the remainder ADLIS (AD plasma from least 
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immunosuppressed) (Fig. 4d). Albumin and AH6809 reversed ADMIS immunosuppression, 
whereas ADLIS were refractory, (Fig. 4d and Supplementary Fig. 5 a-c). This differential 
effect of AH6809 on LIS/MIS samples was also observed in ESLD patients (Supplementary 
Fig. 5d). Analysis of AD patient data (Supplementary Table 1) demonstrated that albumin 
was the only feature that discriminated between MIS and LIS plasma samples (P=0.0012). 
Surprisingly the conventional markers of advanced liver disease, MELD score, Bilirubin or 
INR were unable to differentiate between MIS and LIS (Supplementary Table 1). Receiver 
Operating Characteristic (ROC) analysis of this cohort of 35 patients revealed that a cut off 
level of albumin of <30mg/dl predicted immunosuppression with a sensitivity of 70% (CI 47-
87) and a specificity 67% (CI 35-90).  
 
To examine the therapeutic potential of albumin BDL mice were treated with 20% HAS or 
0.9% saline (0.5ml, i.p.) 2h prior to GBS challenge. In albumin treated mice the mean 
albumin levels rose from 24mg/dl to 32mg/dl. Albumin treatment resulted in significantly 
lower levels of blood bacteria 3h after GBS challenge compared to saline (Fig. 4e). The 
plasma PGE2 concentration was slightly reduced in albumin treated mice (Fig. 4f) but as 
PGE2 measured in plasma reflects both free and albumin bound PGE2, the effect of albumin 
on the immune system may be unrelated to total plasma PGE2 concentration. As albumin has 
no direct bactericidal effect we suggest that it improves immune competence in BDL mice 
via reducing PGE2’s bioavailability.  
 
20% HAS given to patients admitted to hospital with AD (median 200 ml) with albumin <30 
mg/dl raised albumin levels from 23.7±1.7 to 30.1±3.1 mg/ml and reduced in-vitro evidence 
of immunosuppression (Fig. 4g), P<0.05, n=6). Matched samples from patients not given 
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albumin demonstrated persistent immunosuppression. In patients admitted with acute hepatic 
encephalopathy we observed that plasma induced immunosuppression persisted for up to 60 
days following discharge (P<0.001, Fig. 4h) and that administration of 20% HAS on days 1 
& 3 had no effect on long term immunosuppression (samples 8-60 days after albumin). Saline 
had no effect (Supplementary Fig. 5e). 
 
Taken together these findings implicate increased bioavailability of PGE2 as a primary cause 
of innate immune dysfunction and thus vulnerability to infection in cirrhotic patients 
presenting with AD and in ESLD. We accept that other mediators are highly likely to also be 
responsible for cirrhosis-induced immunosuppression such as circulating endotoxin 
secondary to bacterial translocation21. However we suggest that elevated PGE2 is likely to 
represent the primary driver and offers a potential target for immunomodulatory therapy.   
Our studies reveal the likely source of the PGE2 to be peripheral blood mononuclear cells, 
liver Kupffer cells and alveolar macrophages. Increased PGE2 production may be triggered 
by a combination of liver-injury related inflammatory cell infiltrate and gut-bacterial 
translocation resulting in elevated COX activity in these cell types22. Critically, the 
immunosuppressive effect of PGE2 was increased by reduced serum albumin concentration in 
AD patients.  Albumin is known to both bind and catalyse E-series prostaglandins and its 
reduction may be expected to result in elevated PGE2 bioavailability
20. This relationship may 
explain why plasma from stable cirrhosis patients had no immunosuppressive effects despite 
elevated PGE2 (twice control values); this population being protected by normal albumin 
concentrations. Despite the apparent anti-fibrotic properties of PGE2
23 5 days of COX 2 
inhibition did not worsen liver fibrosis.  
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PGE2 mediated immunosuppression was observed in >75 patients with either AD or ESLD 
recruited from 5 sites in two countries and in almost all AD patients from day 2 of their 
admission till at least 60 days following discharge. In this population a serum albumin 
concentration <30mg/dl may be predictive of immunosuppression (reflecting an inverse 
correlation with PGE2 bioavailability). Crucially we have demonstrated that 20% HAS 
infusions given in vivo to achieve a concentration above this level restores (albeit 
temporarily) immune competency, reversing AD-plasma induced impairment of cytokine 
production ex-vivo and both bacterial killing and survival in in vivo mouse models to 
HV/sham levels respectively.  
 
Although effective experimentally, non-steroidal anti-inflammatory drugs (NSAIDS) are 
contraindicated in advanced cirrhosis patients due to increased incidence of renal impairment 
and gastrointestinal bleeding24. Albumin, already safely used to treat cirrhosis-associated 
complications such as spontaneous bacterial peritonitis (SBP)25, appears to selectively 
antagonize PGE2’s effects on the immune system without compromising its protective role in 
other tissues. Recently suggested to exert multimodal beneficial effects in the cirrhotic 
population26,27, we provide mechanistic insight into one of these: its immune restorative 
properties. Stratified, targeted HAS therapy to achieve and maintain serum concentrations at 
near normal concentrations may thus represent an elegant, cheap, and rapidly implementable 
management paradigm to ameliorate PGE2-induced innate immune impairment both 
preventing and treating infection in patients presenting with AD. HAS may also represent a 
therapeutic strategy in ESLD patients28. These management paradigms would clearly require 
validation by large-scale clinical trials. 
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ONLINE METHODS  
Human Models 
Samples were obtained from several sources representing the spectrum of cirrhosis patients 
that vary in vulnerability to infection. Non-cirrhotic liver disease patients were used as a 
control. Informed consent was obtained from all subjects. Consecutively sampled unselected 
plasma samples from these cohorts were used in a blinded fashion for the assays of immune 
function. We were able to gain anonymised patient data for the patients from the DASIMAR 
study for correlation with our laboratory results following the experiments. 
We obtained plasma samples from the following patient cohorts with acutely decompensated 
cirrhosis. Patients with Acute-on-Chronic-Liver-Failure (AoCLF) samples from the 
Predictive utility of DASIMAR as a prognostic biomarker in AoCLF study 
(ClinicalTrials.gov: NCT01071746). Patients with acute encephalopathy from the ALFAE 
study (Efficacy of albumin for acute encephalopathy in patients with cirrhosis, Hospital 
Clinic of Barcelona; ClinicalTrials.gov: NCT00886925). Patients with an acute presentation 
of decompensated liver cirrhosis secondary to alcoholic liver disease from University College 
London Hospital (UCLH). Patients on the liver transplant waiting list, representing end stage 
liver disease (ESLD) were followed up for 24 weeks under the MACHT study (Effect of 
midodrine and albumin in the prevention of complications in cirrhotic patients awaiting liver 
transplantation, Hospital Clinic of Barcelona; ClinicalTrials.gov: NCT00839358). Patients 
with stable cirrhosis (Child’s Pugh A) from The Royal London Hospital outpatient clinic and 
Patients withnon-cirrhotic liver disease (Non-Alcoholic Fatty Liver Disease) from The Royal 
London Hospital outpatient clinic.  
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Ethical approval was granted for all studies. AoCLF samples were obtained from ‘Predictive 
utility of DASIMAR as a prognostic biomarker in AoCLF’ (ClinicalTrials.gov identifier: 
NCT01071746; UCLH NHS Research Ethics Committee number: 08/H0714/8) along with 
age/gender matched healthy volunteer controls. Samples were obtained from patients 
admitted to the Royal Free Hospital on days 1, 2, 5, 6 following admission. Samples from 
patients awaiting transplant originated from MACHT (Effect of midodrine and albumin in the 
prevention of complications in cirrhotic patients awaiting liver transplantation; 
ClinicalTrials.gov identifier: NCT00839358). Patients enrolled to MACHT received 200g 
albumin/placebo on admission with blood sampling at baseline, 4 and 12weeks time-points 
post-intervention. ALFAE (Efficacy of albumin for acute encephalopathy in patients with 
cirrhosis; ClinicalTrials.gov identifier: NCT00886925) provided samples from patients with 
non-terminal cirrhosis (early-phase) randomized to receive either 200g albumin (1L, 20% 
human albumin solution) over 48hours or an equivalent volume of 0.9% saline. Samples were 
drawn prior to intervention and 8-10 days and 30-60 days post. Samples were also acquired 
through on-going local research from University College Hospitals NHS Trust (UCLH) and 
the Royal London Hospitals NHS Trust (Monocyte and macrophage phenotype and function 
in liver failure; Harrow NHS Research Ethics Committee no. 12/LO/0167) were utilised to 
explore its effect on short-term immune function. At UCLH albumin was administered in 
response to clinical indication(s), and samples drawn pre and 24 hours post infusion. 
 
Extraction and analysis of lipid mediators 
Lipid mediators in mice/human plasma were analyzed by liquid chromatography coupled to 
electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) based on protocols 
published previously16. Briefly, samples were collected and stored immediately at −80 °C. 
Plasma Samples (250-500μl for mice, 500–1,000μL for humans) were defrosted on ice and 
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adjusted to 15% (v/v) methanol: water (final volume 4mL). Internal standards, PGB2-d4 (40 
ng) and 12-HETE-d8 (40ng) (Cayman Chemical Company, Ann Arbor, USA) were added 
and the pH of resulting solutions adjusted to 3.0 (1M HCL). Acidified samples were 
immediately applied to preconditioned solid-phase cartridges (C18-E, Phenomenex, 
Macclesfield, UK) and lipid mediators eluted with methyl formate. LC/ESI-MS/MS analysis 
was performed on a HPLC pump (Waters Alliance 2695) coupled to an electrospray 
ionization triple quadruple mass spectrometer (Quattro Ultima, Waters, UK). 
Chromatographic separation was performed on a C18 Luna column (5μm, 150 x 2.0mm, 
Phenomenex) for eicosanoids and a C18 Kinetex column (2.6μm, 100 x 2.1mm, 
Phenomenex) for hydroxy- fatty acids. Analytes were monitored on multiple reaction 
monitoring mode as reported with the following additions: 15-hydroxyeicosatrienoic acid 
(HETrE) m/z 321>221, 10-hydroxydocosahexaenoic acid (HDHA) m/z 343>153, 14-HDHA 
m/z 343>161, 13-HDHA m/z 343>193 and 17-HDHA m/z 343>201. 
 
Human blood analysis and macrophage isolation/culture 
To prepare human monocyte-derived macrophages (MDM) , healthy volunteer mononuclear 
cells were isolated by differential centrifugation (900g, 30min, 20°C) over Lymphoprep™ 
(Axis-Shield) and washed with sterile PBS (Invitrogen™, Life Technologies™)17. Cells were 
resuspended in 10ml RPMI-1640 medium (Invitrogen™, Life Technologies™)) 
supplemented with 100 U.ml-1 of penicillin/100μg.ml-1 streptomycin (Invitrogen™, Life 
Technologies™)) and plated at a density of ∼5 × 106 cells/ml in 8cm2 Nunclon Surface tissue 
culture dishes (Nunc®). After 2h incubation at 37°C (5% CO2), non-adherent cells were 
discarded and 10ml of fresh RPMI supplemented with 10% FBS added (Sigma-Aldrich®) 
(with antibiotics as above). After culture for 5 days at 37°C (5% CO2), with addition of a 
further 10ml of fresh 10% FBS/RPMI after 24h (total 20mls), adherent cells were scraped on 
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day 5 and replated in 96-well culture plates (Nunc®) at equal densities (105/well) in X-Vivo-
15 serum free 0.2% HAS medium (Lonza). Resulting primary MDM, validated by 
morphological inspection, were incubated overnight at 37°C (5% CO2) to adhere prior to 
stimulation with 200ng/ml LPS (Salmonella abortus equi, Enzo Biochem, Inc). To examine 
the effect of plasma/serum on macrophages, these were added to cell culture 30min prior to 
LPS to give a final volume of 25% plasma/serum. Similarly eicosanoids of interest were also 
added to cell culture 30min prior to LPS. AH6809 (50-300μM) was dissolved in X-vivo and 
added to the macrophages 45min prior to plasma.  Macrophage supernatants were collected 
after 24h stimulation with LPS and stored at -80 °C for cytokine analysis by ELISA as 
described. Cell viability was ascertained with calcein AM cell viability assay kit (Biotium, 
Inc). Human serum albumin was obtained from Sigma-Aldrich >99% (agarose gel 
electrophoresis), essentially fatty acid (0.005%) and globulin free.  For bacterial killing, 
Escherichia Coli (clinical isolate, provided by Dr Vanya Gant, Clinical Director for Infection, 
Consultant Microbiologist, UCLH) was added to healthy volunteer macrophages (ratio 100 
E.coli: 1 macrophage) in the presence/absence of plasma from patient/healthy volunteer 
plasma ± AH6809 (50-300μM, Sigma Aldrich Dorset, UK) or albumin (15g/l) as above for 
1h in media without antibiotics. Supernatants were plated on blood agar overnight and CFUs 
counted.  
 
RNA isolation and gene expression studies 
Peripheral blood mononuclear cells (PBMC) were isolated from total blood with the Ficoll 
method (Ficoll-PaqueTM PLUS, GE-Healthcare, Cat. No:17-1440-03) from four patients (3 
males/1female) and six healthy controls (3 males/3 females). The PBMC cell pellet was 
immediately frozen at -80oC until cell lysis and total RNA extraction with the RNeasy Mini 
Kit (Qiagen, Cat. No: 74104). RNA concentration was measured spectrophotometrically at 
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260 nm (Nanodrop8000, Thermo Fishcer), and RNA purity was determined by the 
A260/A280, A230/260 ranges and spectral pattern. 500ng of total RNA were reverse 
transcribed to cDNA using Moloney Murine Leukemia Virus Reverse Transcriptase, RNase 
H Minus, Point Mutant (M-MLV RT (H–) (Promega, Cat No: M368A) and Promega 
oligodTs, random primers and M-MLV X5 RT buffer (Promega). cDNA was then subjected 
to quantitative real-time PCR using an 7900HT ABI thermal cycler (Applied Biosystems), 
SYBGR (Applied Biosystems, Cat. No: 4367659) and in-house designed and optimised 
primers for the genes of interest and internal controls. Primer sequences were:  PTGS1, 
forward primer: TACCAGGTGCTGGATGGAGA, reverse primer: 
CCTTCAGCAGGTCACACAC; PTGS2, forward primer: GTTTTGACATGGGTGGGAAC, 
reverse primer: CCCTCAGACAGCAAAGCCTA, CYPH: forward primer: 
GCCGAGGAAAACCGTGTACT, reverse primer: ACCTTGTCTGCAAACAGCTCA; RPL27 
(ribosomal protein 27), forward primer: TCCAAGGGGATATCCACAGA, reverse primer: 
CATGGGCAAGAAGAAGATCG, RSP20 (ribosomal protein 20), forward primer: 
GGAAACGATCCCACGTCTTA, reverse primer: AGAGGCGCAAAAGAAAAGAA.  
Dissociation curve analysis was performed at 40 cycles to verify the identity of PCR product. 
For data analysis, the comparative threshold cycle values for constitutively expressed CYPH 
were used to normalize loading variations and data are expressed as arbitrary units (AU). 
Gene expression data analysis was also undertaken with the use of RPL27 and RPS20 as 
endogenous controls.  
 
Animal models 
Mice were maintained in a 12h/12h light/dark cycle at 22 ± 1°C and given food and tap water 
ad libitum in accordance with UK Home Office regulations. Studies were performed in male 
C57Bl6/J mice (20-25g) from Charles River UK, Margate, UK. Two models of liver injury 
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were used: Bile duct ligation (BDL, 2 weeks) was performed29 or Carbon Tetrachloride 
(CCL4, Merck, Darmstadt, Germany, 8 weeks) given s.c. (1 ml/kg) twice weekly and 
300mg/L phenobarbital in water30. We used these to investigate whether PGE2 inhibitors 
affected bacterial killing and survival in infection models in vivo. 
Bile duct ligation/sham procedures were carried out under anesthesia (isoflurane 1.5%) as 
described previously18. Carbon tetrachloride (CCL4, Merck, Darmstadt, Germany) was given 
subcutaneously (s.c., 1:1 dissolved in olive oil; 1 ml/kg) twice weekly and 300mg/L 
phenobarbital added to drinking water19. Sham mice received s.c. injections of olive oil. After 
2 weeks for BDL mice or 8 weeks for CCL4 mice, interventional models were undertaken or 
blood and liver were taken and prepared for histology or further experimental use. 
Experiments were performed on CCL4 mice on the same day as the final injection.  
 
Interventional models: peritonitis and intra-venous bacterial inoculation 
Group B Streptococcus (GBS) (NCTC10/84, serotype V) was grown in Todd Hewitt broth 
without agitation at 37°C to an OD600 of 0.4, equivalent to 108 Colony Forming Units 
(CFU)/mL, centrifuged/washed with sterile PBS and injected intraperitoneally (i.p.) at 30x106 
colony forming units (CFUs) in 300μl sterile PBS or for bacterial killing assays. A clinical 
isolate of GBS was provided by Dr Vanya Gant, Clinical Director for Infection, Consultant 
Microbiologist, UCLH and 1x107CFUs in 300μl sterile PBS i.p. was used for mouse survival 
studies; 6x107 CFUs for i.p saline vs albumin infusion studies and 4x107 in 200μl sterile PBS 
for intravenous (i.v.) studies. For bacterial killing assays in mice with/without the non-
selective COX-inhibitor indomethacin (3mg.kg-1 p.o. 1h prior to bacterial challenge, Sigma-
Aldrich®. or equivalent volume of vehicle), heparinized blood was collected 3h after GBS 
injection, centrifuged (10,000g, 4°C, 10min), plated on agar overnight and CFUs counted the 
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following day. For the survival experiments, mice were observed every 6h for up to 80h. In 
accordance with Home Office guidance, mice were humanely culled if they had a “sickness 
score” of 4 or 3 for greater than 24h (Supplementary Table 4). 
   
Cytokine analysis  
Murine cytokine expression profiles were determined using Th1/Th2 10-plex FlowCytomix 
Mouse Kits (Bender MedSystems). Fluorescence was measured on a flow cytometer (BD 
FACSCanto II™, BD bioscience) and data analyzed using manufacturer’s software. The 
expression profile of a cytokine panel in human macrophage supernatants was measured 
using the MSD® Bio-Plex human cytokine assay (Merck, Sharp & Dohme Ltd.). Our assay 
was customized to detect/quantify IL-1, IL-6, IL-8, IL-10 and TNFα. Key cytokine changes 
were confirmed by dedicated ELISA (TNFα and IL10 - mouse eBioscience or human 
Duoset®, R&D systems). All samples were run in duplicate.  
 
Mouse blood analysis, macrophage isolation/culture  
Blood was collected by intracardiac puncture into heparin and centrifuged (10,000g, 4OC, 
10min). Plasma was analyzed for liver and renal function tests using the COBAS® 
INTEGRA 400 plus multianalyser with appropriate diagnostic kits (Roche - Diagnostics) or 
stored at -80°C. Peritoneal macrophages from healthy animals were isolated as described 
previously20 and incubated with/without LPS (Salmonella Typhosa, 0.1μg/mL for 24h; 
Sigma-Aldrich®) in the presence of plasma (50μl) from naïve, sham, BDL or CCL4 mice in 
cell culture media (complete DMEM; Life Technologies™) to give a final concentration of 
25% by volume. In other experiments plasma was added to cell culture, as above, from BDL 
mice given indomethacin (3mg.kg-1 po 6h prior to sampling); the cytochrome P450 inhibitor 
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SKF525A (Enzo® Life Sciences; 50mg.kg-1 s.c. 1h prior to sampling); or the 12/15 
lipoxygenase (LOX) inhibitor Bacalein (Sigma-Aldrich®; 100mg.kg-1 s.c. 90min prior to 
sampling). In experiments examining the effect of the DP1/EP1-3 receptor antagonist 
AH6809 (300μM; Sigma-Aldrich®), this compound was dissolved in DMEM and added to 
macrophages 45min prior to addition of plasma.  Cell viability was ascertained with the 
calcein AM cell viability assay kit (Biotium, Inc) in accordance with manufacturer’s 
instructions. For heat inactivation, plasma was placed at 56°C in a water bath for 1h and 
samples stored overnight at 4°C and used for cell culture the following day. 
 
Immunohistochemistry 
For COX 1 and COX 2 expression, immunohistochemistry was carried out on formalin-fixed, 
wax-embedded mouse tissues using COX 1 polyclonal antibody (Cayman Chemical, 
catalogue number 160109) and COX-2 polyclonal antibody (Cayman Chemical, catalogue 
number 160106) using rabbit anti-mouse as secondary. 
 
Randomisation 
Cages of animals (n=5/cage) were randomly allocation to surgical or chemical-induced liver 
injury. Thereafter, groups of mice were allocated to receive drug intervention, infectious 
stimuli or both. In addition, groups of liver disease mice and sham controls were chosen for 
plasma extraction for ex vivo bioassays, where appropriate. For human studies, randomisation 
was not possible as human monocyte-derive macrophages received plasma from either 
healthy volunteers or from liver disease patients. 
 
Blinding 
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For all mouse and human cell culture and bacteria experiments and mouse survival 
experiments, the investigator was blinded to the sample source during both the experiment 
and analysis of the data.  
 
Statistical analysis  
For calculation of group sizes, from experiments with murine peritonitis, cellular profiles, 
inflammatory protein expression and lipid mediator production is extremely reproducible. We 
found with random allocation of animals to each group that intra-animal replicate variability 
is much less than inter-animal biological variability. An effect size of ~40% of parameter 
mean is considered biologically relevant. Using this and population statistics, to enable 
statistical determination at a P<0.05 in a primary ANOVA screen followed by post-hoc 
Bonferroni corrected T-test at 90% power, a group size of 5 animals is necessary with a 
maximum of 5 groups per experiment. Applying this approach to humans using human 
cirrhotic plasma on humans cells with bacterial killing and TNFα as a readout, a minimum of 
n=10/group was required in order to discern significant changes in immune function. 
Statistical analysis was performed using GraphPad Prism 4 (GraphPad Software). For 
comparisons between multiple groups, 1-way ANOVA with repeated measures was 
performed followed by Bonferroni post-test. Comparisons between 2 groups were made by 2-
tailed (un)paired t test. Differences between time-response curves were assessed by 2-way 
ANOVA. Correlations between variables were calculated using linear regression with 
Pearson statistic. For data not normally distributed (clinical data presented in Supplementary 
Table 1) the Mann-Whitney test was used. P < 0.05 was considered statistically significant. 
No data, either rodent or human, were excluded from analysis.  
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FIGURE LEGENDS 
Figure 1. Elevated PGE2 in plasma of patients admitted to hospital with acute 
decompensation (AD) is immunosuppressive (a) LC/ESI-MS/MS analysis of PGE2 in 
plasma of AD patients (day 1 or 2 of admission) and healthy volunteers. (b) TNFα release 
from human monocyte-derived macrophages stimulated with LPS in the presence of PGF2a, 
PGE2, 5-HETE, 12-HETE and 15-HETE (experiments on cells from n=7 healthy volunteers 
in duplicate). (c) TNFα release from human monocyte-derived macrophages stimulated with 
LPS in the presence  of plasma from AD patients (day 1 or 2 of admission) and healthy 
volunteers with or without the PGE2 EP1-3 antagonist receptor antagonist AH6809, 50μM/ 
300μM (plasma from n=35 patients used with experiments in duplicate).  (d)  Human 
monocyte-derived macrophage bacterial killing in the presence of plasma from AD patients 
(day 1 or 2 of admission) or healthy volunteers with or without AH6809, 50μM (n=8-10). 
TNFα (e) and IL-10 (f) release from human monocyte-derived macrophages stimulated with 
LPS in the presence of plasma from AD patients (day 2 to 6 of admission) and healthy 
volunteers with or without AH6809, 50μM (n= 3-15 patients). Data are represented as mean 
± SEM. * P<0.05 ** P<0.01 ***P<0.001, ANOVA.   
 
Figure 2. Plasma from End Stage Liver Disease patients but not stable cirrhosis or non-
cirrhotic liver disease demonstrates PGE2 mediated immunosuppression. Elevated 
PGE2 is derived from circulating monocytes, kuppfer cells and alveolar macrophages. 
(a) TNFα release from human monocyte-derived macrophages stimulated with LPS in the 
presence of plasma from patients awaiting liver transplant sampled 24 weeks apart and 
healthy volunteers with and without AH6809 (n=13 patients). (b) TNFα release from human 
monocyte-derived macrophages stimulated with LPS in the presence of plasma from stable 
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cirrhosis (Child score A, n=16) or non-cirrhotic liver disease outpatients (n=5) and healthy 
volunteers with and without AH6809. (c) rtPCR of COX-2 and COX-1 in peripheral blood 
mononuclear cells isolated from AD patients and healthy volunteers (n=5 per group). (d) 
Plasma PGE2 concentrations in naïve, sham, bile duct ligation (BDL) and carbon tetrachloride 
(CCL4) liver injury mice (n≥6 mice/group). (e) Immunohistochemical staining for COX 2 in 
liver Kupffer cells and alveolar macrophages, scale bar 50μM. Data are represented as mean 
± SEM. * P<0.05 ** P<0.01 ***P<0.001, ANOVA.     
 
Figure 3. Inhibiting PGE2 reversed impairs bacterial killing and restores survival 
following bacterial infection in mice models of liver injury. (a) TNFα release from 
peritoneal macrophages from naïve mice stimulated with LPS in the presence of plasma from 
healthy (naïve) mice or BDL mice with or without administration of indomethacin, 
SKF525A, LNAME or baicalein prior to blood sampling (n≥6 mice/group). (b) TNFα release 
from peritoneal macrophages from naïve mice stimulated with LPS in the presence of plasma 
from healthy (naïve) mice or CCL4 mice with or without indomethacin prior to blood 
sampling or AH6809 (300μM) added in vitro to cell culture. Blood bacterial counts 3 hours 
following either (c) intraperitoneal or (d) intravenous Group B streptococcus administration 
to sham or BDL mice (with or without indomethacin pretreatment) (n≥8 mice/group). (e) 
Kaplan-Meier survival curves of sham and BDL mice (with or without indomethacin 
pretreatment) following intraperitoneal Group B streptococcus administration. Haematoxylin 
and eosin stain of liver from CCL4 liver mice treated with (f) or without (g5 days of 
celecoxib, scale bar 50 μM. Data are represented as mean ± SEM. * P<0.05 ** P<0.01 
***P<0.001, ANOVA.   
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Figure 4. PGE2-mediated immunosuppression by AD plasma is improved by albumin. 
(a) Correlation graph of LPS stimulated human monocyte-derived macrophage TNFα 
synthesis in the presence of AD plasma expressed by that plasma samples’ PGE2 
concentration divided by its albumin concentration. (b) LPS stimulated monocyte-derived 
macrophage TNFα synthesis in the presence of AD plasma samples compared with the 
same AD samples that have had >99% purified human serum albumin added in vitro to 
restore mean levels to 40 g/l (n=19 patients, experiments in duplicate). (c) LPS stimulated 
monocyte-derived macrophage TNFα synthesis in the presence of increasing concentrations 
of PGE2 with or without addition of 40mg/dl of >99% purified human serum albumin. (d) 
LPS stimulated monocyte-derived macrophage TNFα synthesis in the presence of AD plasma 
samples from the most immunosuppressed (ADMIS) and the  least immunosuppressed (ADLIS) 
(AD plasma from) compared with the same AD samples that have had >99% purified human 
serum albumin added in vitro to restore mean levels to 40 g/l. (e) 3 hour blood bacterial 
counts from BDL mice given  0.5ml of 20% Human Albumin Solution (HAS) 
subcutaneously compared to normal saline (0.9%) prior to intraperitoneal Group B 
streptococcus administration(n=10/group). (f) PGE2 plasma concentrations 3 hours after 
intraperitoneal Group B streptococcus administration from BDL mice given either 20% HAS 
or normal saline prior to bacterial administration (n=5). (g) LPS-stimulated human monocyte-
derived macrophages TNFα synthesis in the presence of AD plasma samples from patients 
pre and post infusion of 20% HAS (median 200ml) (n=6) or plasma samples taken 1 day 
apart in patients not treated with 20& HAS. (h) LPS-stimulated human monocyte-derived 
macrophages TNFα synthesis in the presence of healthy volunteer or AD plasma samples in 
patients administered 20% HAS on days 1(400-600ml) & 3 (200-400ml) of admission with 
samples obtained during admission and at 10-20 or 30-60 days post discharge (n=10). Data 
are represented as mean ± SEM.  * P<0.05 ** P<0.01 ***P<0.001, ANOVA.   
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 Supplementary Table 1. Patient Clinical Characteristics from DASIMAR study 
 ADMIS n=22 
(median, IQR) 
ADLIS n =13 
(median, IQR) 
P 
value 
Overall n=35 
(median, IQR) 
% 63 27   
Age 49.5 (46.5-64.5) 54 (48-70) 0.56 52 (47-65) 
Sex (males) 16 (73%) 6 (46%)  22 (63%) 
Albumin 28 (24-30) 30 (28-31.5) 0.0012 29 (27-31) 
INR 1.7 (1.4-2.04) 1.6 (1.23-2) 0.93 1.7 (1.4-2) 
Creatinine 62 (47-109) 62 (47.5-122) 0.54 62 (49-108) 
MELD score 19.4 (15.6-21.8) 18.39 (12.1-21.4) 0.93 19 (14.2-23) 
Positive 
microbiology 
6 3  9 
Died during 
admission 
2 1  3 
Died within 6 
months 
7 4  11 
Length of stay 
(days) 
11.5 (8-28) 10 (5.5-19) 0.22 11 (7-25) 
CRP 28 (115-50.5) 23 (5-43.5) 0.24 26 (13-49) 
Bilirubin 78 (34-119) 53 (19-73) 0.87 67.5 (24-104) 
Cause of 
cirrhosis 
15 Alcohol (68%)      6 Alcohol (46%) 21 Alcohol (60%) 
3 NASH 3 NASH  6 NASH (17%) 
1 PBC 1 PBC  2 PBC 
1 Sarcoid       1 Cryptogenic 2 HCV 
1 Congenital hepatic 
fibrosis 
1 HBV  1 HBV 
1 HCV 1 HCV  1 Congenital hepatic 
fibrosis 
PGE2 0.12 (0.09-0.16); n=7 0.065 (0.035-0.085); 
n=6 
0.005 0.09 (0.065-0.13); n=13 
PGE2/albumin 0.0041 (0.0036-
0.0058); n=7 
0.002 (0.001-
0.0028); n=6 
0.001 0.003571 (0.0022-0.0049); 
n=13 
NH3 208 (128-260.5); n=5 151; n=1  204 (133-236); n=6 
Ischemia 
modified 
albumin ratio 
(IMAR) 
0.025 (0.014-0.06); 
n=10 
0.011 (0.005-0.02); 
n=5 
0.075 0.017(0.01-0.04); n=15 
 
 
 
 Supplementary Table 2. Lipid levels in human plasma 
 
 
Healthy Volunteers 
(n=8) (ng/ml) 
AD Patients  
(n=14) (ng/ml) 
PGE2 0.015(0.003) 0.091(0.01)*** 
PGD2 0 0 
PGF2A 0 0.8(0.08)*** 
PGE1 0 0 
PGD1 0 0 
TXB2 0.31(0.1) 0.77(0.11) 
9-HODE 5.45(1.63) 4.87(0.51) 
13-HODE 8.27(2.7) 6.91(0.69) 
5-HETE 0.11(0.044) 0.43(0.1)* 
8-HETE 0 0.15(0.02) 
11-HETE 0 0.06(0.02) 
15-HETE 0 0.72(0.1)*** 
12-HETE 0.66(0.26) 1.28(0.28) 
15-HETrE 0 0.39(0.03)*** 
 
   * P<0.05 ** P<0.01 ***P<0.001, t-test cirrhosis vs healthy volunteers 
Supplementary Table 3. Mouse clinical and biochemical data 
 Naïve 
mouse 
Sham 
mouse 
BDL 
mouse 
CCL4 
mouse 
Albumin 29(3) 29(1) 24(2)** 28.5(1) 
ALT 20(9) 26(2.4) 340(33)*** 539(158)** 
AST 68(11) 94(18) 496(55)  
Total Protein 41(3) 43(2) 32(2.7)**  
Glucose 15(0.2) 12(1) 6(1)  
Bilirubin 12(4) 17(2.9) 380(35)***  
Creatinine 9(0.7) 11(0.3) 27(2.6)**  
Urea 9(0.7) 8(0.4) 9(0.9)  
TNFα ρg.ml-1 4(2.6) 53(16) 60(25)  
Cardiac output 28.1(0.9) 26.7(1.5) 16(1)***  
Mean arterial 
pressure (mmHg) 
- 112(4) 99(4)*  
Core Temperature 37.8(0.2) 37.6 (0.1) 35.1(0.2)** 37.8(0.2) 
Age at surgery 11 weeks 11 weeks 11 weeks  
Weight (g) 27.8(0.6) 27(0.4) 19.4(0.3) 28(0.4) 
 
  * P<0.05 ** P<0.01 ***P<0.001, t-test for BDL or CCL4 vs naïve or sham mice 
 
Supplementary Table 4. Murine Sickness score following bacterial peritonitis. Mice culled if score of 4 at 
any point or score of 3 for greater than 24h 
Clinical Feature Score 
Piloerection 1 
Slow movement 1 
Hunched posture 1 
Pus in eye(s) 3 
Failure to move 4 
Weight loss >25% 4 
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Supplementary Methods Section 
 
Extraction and analysis of lipid mediators 
Lipid mediators in mice/human plasma were analyzed by liquid chromatography coupled to 
electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) based on protocols 
published previously16. Briefly, samples were collected and stored immediately at −80 °C. 
Plasma Samples (250-500μl for mice, 500–1,000μL for humans) were defrosted on ice and 
adjusted to 15% (v/v) methanol: water (final volume 4mL). Internal standards, PGB2-d4 (40 
ng) and 12-HETE-d8 (40ng) (Cayman Chemical Company, Ann Arbor, USA) were added and 
the pH of resulting solutions adjusted to 3.0 (1M HCL). Acidified samples were immediately 
applied to preconditioned solid-phase cartridges (C18-E, Phenomenex, Macclesfield, UK) and 
lipid mediators eluted with methyl formate. LC/ESI-MS/MS analysis was performed on a 
HPLC pump (Waters Alliance 2695) coupled to an electrospray ionization triple quadruple 
mass spectrometer (Quattro Ultima, Waters, UK). Chromatographic separation was performed 
on a C18 Luna column (5μm, 150 x 2.0mm, Phenomenex) for eicosanoids and a C18 Kinetex 
column (2.6μm, 100 x 2.1mm, Phenomenex) for hydroxy- fatty acids. Analytes were monitored 
on multiple reaction monitoring mode as reported with the following additions: 15-
hydroxyeicosatrienoic acid (HETrE) m/z 321>221, 10-hydroxydocosahexaenoic acid (HDHA) 
m/z 343>153, 14-HDHA m/z 343>161, 13-HDHA m/z 343>193 and 17-HDHA m/z 343>201. 
 
Human samples 
Samples were obtained from several sources representing the spectrum of cirrhosis patients 
which vary in vulnerability to infection. Non-cirrhotic liver disease patients were used as a 
control.  
(i) Acutely decompensated patients:  
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a. AoCLF samples - Predictive utility of DASIMAR as a prognostic biomarker in AoCLF 
(ClinicalTrials.gov: NCT01071746).  
b. Acute encephalopathy - ALFAE (Efficacy of albumin for acute encephalopathy in patients 
with cirrhosis, Hospital Clinic of Barcelona; ClinicalTrials.gov: NCT00886925).  
c. First presentation with decompensation secondary to alcoholic liver disease from University 
College Hospital (UCLH). 
(ii) Patients on the liver transplant waiting list for a 24 week follow up period representing end 
stage liver disease - MACHT (Effect of midodrine and albumin in the prevention of 
complications in cirrhotic patients awaiting liver transplantation, Hospital Clinic of Barcelona; 
ClinicalTrials.gov: NCT00839358).  
(iii) Stable cirrhosis (Child’s Pugh A) from The Royal London Hospital outpatient clinic. 
(iv) Non-cirrhotic liver disease (Non-Alcoholic Fatty Liver Disease) from The Royal London 
Hospital outpatient clinic.  
Ethical approval was granted for all studies. AoCLF samples were obtained from ‘Predictive 
utility of DASIMAR as a prognostic biomarker in AoCLF’ (ClinicalTrials.gov identifier: 
NCT01071746; UCLH NHS Research Ethics Committee number: 08/H0714/8) along with 
age/gender matched healthy volunteer controls. Samples were obtained from patients admitted 
to the Royal Free Hospital on days 1, 2, 5, 6 following admission. Samples from patients 
awaiting transplant originated from MACHT (Effect of midodrine and albumin in the 
prevention of complications in cirrhotic patients awaiting liver transplantation; 
ClinicalTrials.gov identifier: NCT00839358). Patients enrolled to MACHT received 200g 
albumin/placebo on admission with blood sampling at baseline, 4 and 12weeks time-points 
post-intervention. ALFAE (Efficacy of albumin for acute encephalopathy in patients with 
cirrhosis; ClinicalTrials.gov identifier: NCT00886925) provided samples from patients with 
non-terminal cirrhosis (early-phase) randomized to receive either 200g albumin (1L, 20% 
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human albumin solution) over 48hours or an equivalent volume of 0.9% saline. Samples were 
drawn prior to intervention and 8-10 days and 30-60 days post. Samples were also acquired 
through on-going local research from University College Hospitals NHS Trust (UCLH) and 
the Royal London Hospitals NHS Trust (Monocyte and macrophage phenotype and function 
in liver failure; Harrow NHS Research Ethics Committee no. 12/LO/0167) were utilised to 
explore its effect on short-term immune function. At UCLH albumin was administered in 
response to clinical indication(s), and samples drawn pre and 24 hours post infusion. 
 
Human blood analysis and macrophage isolation/culture 
To prepare human monocyte-derived macrophages (MDM) , healthy volunteer mononuclear 
cells were isolated by differential centrifugation (900g, 30min, 20°C) over Lymphoprep™ 
(Axis-Shield) and washed with sterile PBS (Invitrogen™, Life Technologies™)17. Cells were 
resuspended in 10ml RPMI-1640 medium (Invitrogen™, Life Technologies™)) supplemented 
with 100 U.ml-1 of penicillin/100μg.ml-1 streptomycin (Invitrogen™, Life Technologies™)) 
and plated at a density of ∼5 × 106 cells/ml in 8cm2 Nunclon Surface tissue culture dishes 
(Nunc®). After 2h incubation at 37°C (5% CO2), non-adherent cells were discarded and 10ml 
of fresh RPMI supplemented with 10% FBS added (Sigma-Aldrich®) (with antibiotics as 
above). After culture for 5 days at 37°C (5% CO2), with addition of a further 10ml of fresh 
10% FBS/RPMI after 24h (total 20mls), adherent cells were scraped on day 5 and replated in 
96-well culture plates (Nunc®) at equal densities (105/well) in X-Vivo-15 serum free 0.2% 
HAS medium (Lonza). Resulting primary MDM, validated by morphological inspection, were 
incubated overnight at 37°C (5% CO2) to adhere prior to stimulation with 200ng/ml LPS 
(Salmonella abortus equi, Enzo Biochem, Inc). To examine the effect of plasma/serum on 
macrophages, these were added to cell culture 30min prior to LPS to give a final volume of 
25% plasma/serum. Similarly eicosanoids of interest were also added to cell culture 30min 
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prior to LPS. AH6809 (50-300μM) was dissolved in X-vivo and added to the macrophages 
45min prior to plasma.  Macrophage supernatants were collected after 24h stimulation with 
LPS and stored at -80 °C for cytokine analysis by ELISA as described. Cell viability was 
ascertained with calcein AM cell viability assay kit (Biotium, Inc). Human serum albumin was 
obtained from Sigma-Aldrich >99% (agarose gel electrophoresis), essentially fatty acid 
(0.005%) and globulin free.  For bacterial killing, Escherichia Coli (clinical isolate, provided 
by Dr Vanya Gant, Clinical Director for Infection, Consultant Microbiologist, UCLH) was 
added to healthy volunteer macrophages (ratio 100 E.coli: 1 macrophage) in the 
presence/absence of plasma from patient/healthy volunteer plasma ± AH6809 (50-300μM, 
Sigma Aldrich Dorset, UK) or albumin (15g/l) as above for 1h in media without antibiotics. 
Supernatants were plated on blood agar overnight and CFUs counted.  
 
RNA isolation and gene expression studies 
Peripheral blood mononuclear cells (PBMC) were isolated from total blood with the Ficoll 
method (Ficoll-PaqueTM PLUS, GE-Healthcare, Cat. No:17-1440-03) from four patients (3 
males/1female) and six healthy controls (3 males/3 females). The PBMC cell pellet was 
immediately frozen at -80oC until cell lysis and total RNA extraction with the RNeasy Mini 
Kit (Qiagen, Cat. No: 74104). RNA concentration was measured spectrophotometrically at 260 
nm (Nanodrop8000, Thermo Fishcer), and RNA purity was determined by the A260/A280, 
A230/260 ranges and spectral pattern. 500ng of total RNA were reverse transcribed to cDNA 
using Moloney Murine Leukemia Virus Reverse Transcriptase, RNase H Minus, Point Mutant 
(M-MLV RT (H–) (Promega, Cat No: M368A) and Promega oligodTs, random primers and 
M-MLV X5 RT buffer (Promega). cDNA was then subjected to quantitative real-time PCR 
using an 7900HT ABI thermal cycler (Applied Biosystems), SYBGR (Applied Biosystems, 
Cat. No: 4367659) and in-house designed and optimised primers for the genes of interest and 
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internal controls. Primer sequences were:  PTGS1, forward primer: 
TACCAGGTGCTGGATGGAGA, reverse primer: CCTTCAGCAGGTCACACAC; PTGS2, 
forward primer: GTTTTGACATGGGTGGGAAC, reverse primer: 
CCCTCAGACAGCAAAGCCTA, CYPH: forward primer: GCCGAGGAAAACCGTGTACT, 
reverse primer: ACCTTGTCTGCAAACAGCTCA; RPL27 (ribosomal protein 27), forward 
primer: TCCAAGGGGATATCCACAGA, reverse primer: CATGGGCAAGAAGAAGATCG, 
RSP20 (ribosomal protein 20), forward primer: GGAAACGATCCCACGTCTTA, reverse 
primer: AGAGGCGCAAAAGAAAAGAA.  Dissociation curve analysis was performed at 40 
cycles to verify the identity of PCR product. For data analysis, the comparative threshold cycle 
values for constitutively expressed CYPH were used to normalize loading variations and data 
are expressed as arbitrary units (AU). Gene expression data analysis was also undertaken with 
the use of RPL27 and RPS20 as endogenous controls.  
 
Animal models 
Bile duct ligation/sham procedures were carried out under anesthesia (isoflurane 1.5%) as 
described previously18. Carbon tetrachloride (CCL4, Merck, Darmstadt, Germany) was given 
subcutaneously (s.c., 1:1 dissolved in olive oil; 1 ml/kg) twice weekly and 300mg/L 
phenobarbital added to drinking water19. Sham mice received s.c. injections of olive oil. After 
2 weeks for BDL mice or 8 weeks for CCL4 mice, interventional models were undertaken or 
blood and liver were taken and prepared for histology or further experimental use. Experiments 
were performed on CCL4 mice on the same day as the final injection.  
 
Interventional models: peritonitis and intra-venous bacterial inoculation 
Group B Streptococcus (GBS) (NCTC10/84, serotype V) was grown in Todd Hewitt broth 
without agitation at 37°C to an OD600 of 0.4, equivalent to 108 Colony Forming Units 
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(CFU)/mL, centrifuged/washed with sterile PBS and injected intraperitoneally (i.p.) at 30x106 
colony forming units (CFUs) in 300μl sterile PBS or for bacterial killing assays. A clinical 
isolate of GBS was provided by Dr Vanya Gant, Clinical Director for Infection, Consultant 
Microbiologist, UCLH and 1x107CFUs in 300μl sterile PBS i.p. was used for mouse survival 
studies; 6x107 CFUs for i.p saline vs albumin infusion studies and 4x107 in 200μl sterile PBS 
for intravenous (i.v.) studies. For bacterial killing assays in mice with/without the non-selective 
COX-inhibitor indomethacin (3mg.kg-1 p.o. 1h prior to bacterial challenge, Sigma-Aldrich®. 
or equivalent volume of vehicle), heparinized blood was collected 3h after GBS injection, 
centrifuged (10,000g, 4°C, 10min), plated on agar overnight and CFUs counted the following 
day. For the survival experiments, mice were observed every 6h for up to 80h. In accordance 
with Home Office guidance, mice were humanely culled if they had a “sickness score” of 4 or 
3 for greater than 24h (Supplementary Table 2). 
   
Cytokine analysis  
Murine cytokine expression profiles were determined using Th1/Th2 10-plex FlowCytomix 
Mouse Kits (Bender MedSystems). Fluorescence was measured on a flow cytometer (BD 
FACSCanto II™, BD bioscience) and data analyzed using manufacturer’s software. The 
expression profile of a cytokine panel in human macrophage supernatants was measured using 
the MSD® Bio-Plex human cytokine assay (Merck, Sharp & Dohme Ltd.). Our assay was 
customized to detect/quantify IL-1, IL-6, IL-8, IL-10 and TNFα. Key cytokine changes were 
confirmed by dedicated ELISA (TNFα and IL10 - mouse eBioscience or human Duoset®, R&D 
systems). All samples were run in duplicate.  
 
Mouse blood analysis, macrophage isolation/culture  
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Blood was collected by intracardiac puncture into heparin and centrifuged (10,000g, 4OC, 
10min). Plasma was analyzed for liver and renal function tests using the COBAS® INTEGRA 
400 plus multianalyser with appropriate diagnostic kits (Roche - Diagnostics) or stored at -
80°C. Peritoneal macrophages from healthy animals were isolated as described previously20 
and incubated with/without LPS (Salmonella Typhosa, 0.1μg/mL for 24h; Sigma-Aldrich®) in 
the presence of plasma (50μl) from naïve, sham, BDL or CCL4 mice in cell culture media 
(complete DMEM; Life Technologies™) to give a final concentration of 25% by volume. In 
other experiments plasma was added to cell culture, as above, from BDL mice given 
indomethacin (3mg.kg-1 po 6h prior to sampling); the cytochrome P450 inhibitor SKF525A 
(Enzo® Life Sciences; 50mg.kg-1 s.c. 1h prior to sampling); or the 12/15 lipoxygenase (LOX) 
inhibitor Bacalein (Sigma-Aldrich®; 100mg.kg-1 s.c. 90min prior to sampling). In experiments 
examining the effect of the DP1/EP1-3 receptor antagonist AH6809 (300μM; Sigma-
Aldrich®), this compound was dissolved in DMEM and added to macrophages 45min prior to 
addition of plasma.  Cell viability was ascertained with the calcein AM cell viability assay kit 
(Biotium, Inc) in accordance with manufacturer’s instructions. For heat inactivation, plasma 
was placed at 56°C in a water bath for 1h and samples stored overnight at 4°C and used for cell 
culture the following day. 
 
Immunohistochemistry 
For COX 1 and COX 2 expression, immunohistochemistry was carried out on formalin-fixed, 
wax-embedded mouse tissues using COX 1 polyclonal antibody (Cayman Chemical, catalogue 
number 160109) and COX-2 polyclonal antibody (Cayman Chemical, catalogue number 
160106) using rabbit anti-mouse as secondary. 
ONLINE METHODS  
Human Models 
Samples were obtained from several sources representing the spectrum of cirrhosis patients 
that vary in vulnerability to infection. Non-cirrhotic liver disease patients were used as a 
control. Informed consent was obtained from all subjects. Consecutively sampled unselected 
plasma samples from these cohorts were used in a blinded fashion for the assays of immune 
function. We were able to gain anonymised patient data for the patients from the DASIMAR 
study for correlation with our laboratory results following the experiments. 
Acutely decompensated patients:  
a. AoCLF samples - Predictive utility of DASIMAR as a prognostic biomarker in AoCLF 
(ClinicalTrials.gov: NCT01071746).  
b. Acute encephalopathy - ALFAE (Efficacy of albumin for acute encephalopathy in patients 
with cirrhosis, Hospital Clinic of Barcelona; ClinicalTrials.gov: NCT00886925).  
c. First presentation with decompensation secondary to alcoholic liver disease from University 
College London Hospital (UCLH). 
(ii) Patients on the liver transplant waiting list, representing ESLD. These were followed up for 
24 weeks - MACHT (Effect of midodrine and albumin in the prevention of complications in 
cirrhotic patients awaiting liver transplantation, Hospital Clinic of Barcelona; 
ClinicalTrials.gov: NCT00839358).  
(iii) Stable cirrhosis (Child’s Pugh A) from The Royal London Hospital outpatient clinic. 
(iv) Non-cirrhotic liver disease (Non-Alcoholic Fatty Liver Disease) from The Royal London 
Hospital outpatient clinic.  
Ethical approval was granted for all studies (see supplementary methods). 
  
Human samples 
Samples were obtained from several sources representing the spectrum of cirrhosis patients 
that vary in vulnerability to infection. Non-cirrhotic liver disease patients were used as a 
control. Informed consent was obtained from all subjects. Consecutively sampled unselected 
plasma samples from these cohorts were used in a blinded fashion for the assays of immune 
function. We were able to gain anonymised patient data for the patients from the DASIMAR 
study for correlation with our laboratory results following the experiments  
(i) Acutely decompensated patients:  
a. AoCLF samples - Predictive utility of DASIMAR as a prognostic biomarker in AoCLF 
(ClinicalTrials.gov: NCT01071746).  
b. Acute encephalopathy - ALFAE (Efficacy of albumin for acute encephalopathy in patients 
with cirrhosis, Hospital Clinic of Barcelona; ClinicalTrials.gov: NCT00886925).  
c. First presentation with decompensation secondary to alcoholic liver disease from University 
College Hospital (UCLH). 
(ii) Patients on the liver transplant waiting list for a 24 week follow up period representing end 
stage liver disease - MACHT (Effect of midodrine and albumin in the prevention of 
complications in cirrhotic patients awaiting liver transplantation, Hospital Clinic of Barcelona; 
ClinicalTrials.gov: NCT00839358).  
(iii) Stable cirrhosis (Child’s Pugh A) from The Royal London Hospital outpatient clinic. 
(iv) Non-cirrhotic liver disease (Non-Alcoholic Fatty Liver Disease) from The Royal London 
Hospital outpatient clinic.  
Ethical approval was granted for all studies. AoCLF samples were obtained from ‘Predictive 
utility of DASIMAR as a prognostic biomarker in AoCLF’ (ClinicalTrials.gov identifier: 
NCT01071746; UCLH NHS Research Ethics Committee number: 08/H0714/8) along with 
age/gender matched healthy volunteer controls. Samples were obtained from patients admitted 
to the Royal Free Hospital on days 1, 2, 5, 6 following admission. Samples from patients 
awaiting transplant originated from MACHT (Effect of midodrine and albumin in the 
prevention of complications in cirrhotic patients awaiting liver transplantation; 
ClinicalTrials.gov identifier: NCT00839358). Patients enrolled to MACHT received 200g 
albumin/placebo on admission with blood sampling at baseline, 4 and 12weeks time-points 
post-intervention. ALFAE (Efficacy of albumin for acute encephalopathy in patients with 
cirrhosis; ClinicalTrials.gov identifier: NCT00886925) provided samples from patients with 
non-terminal cirrhosis (early-phase) randomized to receive either 200g albumin (1L, 20% 
human albumin solution) over 48hours or an equivalent volume of 0.9% saline. Samples were 
drawn prior to intervention and 8-10 days and 30-60 days post. Samples were also acquired 
through on-going local research from University College Hospitals NHS Trust (UCLH) and 
the Royal London Hospitals NHS Trust (Monocyte and macrophage phenotype and function 
in liver failure; Harrow NHS Research Ethics Committee no. 12/LO/0167) were utilised to 
explore its effect on short-term immune function. At UCLH albumin was administered in 
response to clinical indication(s), and samples drawn pre and 24 hours post infusion. 
 
Extraction and analysis of lipid mediators 
Lipid mediators in mice/human plasma were analyzed by liquid chromatography coupled to 
electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) based on protocols 
published previously16. Briefly, samples were collected and stored immediately at −80 °C. 
Plasma Samples (250-500μl for mice, 500–1,000μL for humans) were defrosted on ice and 
adjusted to 15% (v/v) methanol: water (final volume 4mL). Internal standards, PGB2-d4 (40 
ng) and 12-HETE-d8 (40ng) (Cayman Chemical Company, Ann Arbor, USA) were added and 
the pH of resulting solutions adjusted to 3.0 (1M HCL). Acidified samples were immediately 
applied to preconditioned solid-phase cartridges (C18-E, Phenomenex, Macclesfield, UK) and 
lipid mediators eluted with methyl formate. LC/ESI-MS/MS analysis was performed on a 
HPLC pump (Waters Alliance 2695) coupled to an electrospray ionization triple quadruple 
mass spectrometer (Quattro Ultima, Waters, UK). Chromatographic separation was performed 
on a C18 Luna column (5μm, 150 x 2.0mm, Phenomenex) for eicosanoids and a C18 Kinetex 
column (2.6μm, 100 x 2.1mm, Phenomenex) for hydroxy- fatty acids. Analytes were monitored 
on multiple reaction monitoring mode as reported with the following additions: 15-
hydroxyeicosatrienoic acid (HETrE) m/z 321>221, 10-hydroxydocosahexaenoic acid (HDHA) 
m/z 343>153, 14-HDHA m/z 343>161, 13-HDHA m/z 343>193 and 17-HDHA m/z 343>201. 
 
Human blood analysis and macrophage isolation/culture 
To prepare human monocyte-derived macrophages (MDM) , healthy volunteer mononuclear 
cells were isolated by differential centrifugation (900g, 30min, 20°C) over Lymphoprep™ 
(Axis-Shield) and washed with sterile PBS (Invitrogen™, Life Technologies™)17. Cells were 
resuspended in 10ml RPMI-1640 medium (Invitrogen™, Life Technologies™)) supplemented 
with 100 U.ml-1 of penicillin/100μg.ml-1 streptomycin (Invitrogen™, Life Technologies™)) 
and plated at a density of ∼5 × 106 cells/ml in 8cm2 Nunclon Surface tissue culture dishes 
(Nunc®). After 2h incubation at 37°C (5% CO2), non-adherent cells were discarded and 10ml 
of fresh RPMI supplemented with 10% FBS added (Sigma-Aldrich®) (with antibiotics as 
above). After culture for 5 days at 37°C (5% CO2), with addition of a further 10ml of fresh 
10% FBS/RPMI after 24h (total 20mls), adherent cells were scraped on day 5 and replated in 
96-well culture plates (Nunc®) at equal densities (105/well) in X-Vivo-15 serum free 0.2% 
HAS medium (Lonza). Resulting primary MDM, validated by morphological inspection, were 
incubated overnight at 37°C (5% CO2) to adhere prior to stimulation with 200ng/ml LPS 
(Salmonella abortus equi, Enzo Biochem, Inc). To examine the effect of plasma/serum on 
macrophages, these were added to cell culture 30min prior to LPS to give a final volume of 
25% plasma/serum. Similarly eicosanoids of interest were also added to cell culture 30min 
prior to LPS. AH6809 (50-300μM) was dissolved in X-vivo and added to the macrophages 
45min prior to plasma.  Macrophage supernatants were collected after 24h stimulation with 
LPS and stored at -80 °C for cytokine analysis by ELISA as described. Cell viability was 
ascertained with calcein AM cell viability assay kit (Biotium, Inc). Human serum albumin was 
obtained from Sigma-Aldrich >99% (agarose gel electrophoresis), essentially fatty acid 
(0.005%) and globulin free.  For bacterial killing, Escherichia Coli (clinical isolate, provided 
by Dr Vanya Gant, Clinical Director for Infection, Consultant Microbiologist, UCLH) was 
added to healthy volunteer macrophages (ratio 100 E.coli: 1 macrophage) in the 
presence/absence of plasma from patient/healthy volunteer plasma ± AH6809 (50-300μM, 
Sigma Aldrich Dorset, UK) or albumin (15g/l) as above for 1h in media without antibiotics. 
Supernatants were plated on blood agar overnight and CFUs counted.  
 
RNA isolation and gene expression studies 
Peripheral blood mononuclear cells (PBMC) were isolated from total blood with the Ficoll 
method (Ficoll-PaqueTM PLUS, GE-Healthcare, Cat. No:17-1440-03) from four patients (3 
males/1female) and six healthy controls (3 males/3 females). The PBMC cell pellet was 
immediately frozen at -80oC until cell lysis and total RNA extraction with the RNeasy Mini 
Kit (Qiagen, Cat. No: 74104). RNA concentration was measured spectrophotometrically at 260 
nm (Nanodrop8000, Thermo Fishcer), and RNA purity was determined by the A260/A280, 
A230/260 ranges and spectral pattern. 500ng of total RNA were reverse transcribed to cDNA 
using Moloney Murine Leukemia Virus Reverse Transcriptase, RNase H Minus, Point Mutant 
(M-MLV RT (H–) (Promega, Cat No: M368A) and Promega oligodTs, random primers and 
M-MLV X5 RT buffer (Promega). cDNA was then subjected to quantitative real-time PCR 
using an 7900HT ABI thermal cycler (Applied Biosystems), SYBGR (Applied Biosystems, 
Cat. No: 4367659) and in-house designed and optimised primers for the genes of interest and 
internal controls. Primer sequences were:  PTGS1, forward primer: 
TACCAGGTGCTGGATGGAGA, reverse primer: CCTTCAGCAGGTCACACAC; PTGS2, 
forward primer: GTTTTGACATGGGTGGGAAC, reverse primer: 
CCCTCAGACAGCAAAGCCTA, CYPH: forward primer: GCCGAGGAAAACCGTGTACT, 
reverse primer: ACCTTGTCTGCAAACAGCTCA; RPL27 (ribosomal protein 27), forward 
primer: TCCAAGGGGATATCCACAGA, reverse primer: CATGGGCAAGAAGAAGATCG, 
RSP20 (ribosomal protein 20), forward primer: GGAAACGATCCCACGTCTTA, reverse 
primer: AGAGGCGCAAAAGAAAAGAA.  Dissociation curve analysis was performed at 40 
cycles to verify the identity of PCR product. For data analysis, the comparative threshold cycle 
values for constitutively expressed CYPH were used to normalize loading variations and data 
are expressed as arbitrary units (AU). Gene expression data analysis was also undertaken with 
the use of RPL27 and RPS20 as endogenous controls.  
 
Animal models 
Mice were maintained in a 12h/12h light/dark cycle at 22 ± 1°C and given food and tap water 
ad libitum in accordance with UK Home Office regulations. Studies were performed in male 
C57Bl6/J mice (20-25g) from Charles River UK, Margate, UK. Two models of liver injury 
were used: Bile duct ligation (BDL, 2 weeks) was performed37 or Carbon Tetrachloride (CCL4, 
Merck, Darmstadt, Germany, 8 weeks) given s.c. (1 ml/kg) twice weekly and 300mg/L 
phenobarbital in water38. We used these to investigate whether PGE2 inhibitors affected 
bacterial killing and survival in infection models in vivo. 
Bile duct ligation/sham procedures were carried out under anesthesia (isoflurane 1.5%) as 
described previously18. Carbon tetrachloride (CCL4, Merck, Darmstadt, Germany) was given 
subcutaneously (s.c., 1:1 dissolved in olive oil; 1 ml/kg) twice weekly and 300mg/L 
phenobarbital added to drinking water19. Sham mice received s.c. injections of olive oil. After 
2 weeks for BDL mice or 8 weeks for CCL4 mice, interventional models were undertaken or 
blood and liver were taken and prepared for histology or further experimental use. Experiments 
were performed on CCL4 mice on the same day as the final injection.  
 
Interventional models: peritonitis and intra-venous bacterial inoculation 
Group B Streptococcus (GBS) (NCTC10/84, serotype V) was grown in Todd Hewitt broth 
without agitation at 37°C to an OD600 of 0.4, equivalent to 108 Colony Forming Units 
(CFU)/mL, centrifuged/washed with sterile PBS and injected intraperitoneally (i.p.) at 30x106 
colony forming units (CFUs) in 300μl sterile PBS or for bacterial killing assays. A clinical 
isolate of GBS was provided by Dr Vanya Gant, Clinical Director for Infection, Consultant 
Microbiologist, UCLH and 1x107CFUs in 300μl sterile PBS i.p. was used for mouse survival 
studies; 6x107 CFUs for i.p saline vs albumin infusion studies and 4x107 in 200μl sterile PBS 
for intravenous (i.v.) studies. For bacterial killing assays in mice with/without the non-selective 
COX-inhibitor indomethacin (3mg.kg-1 p.o. 1h prior to bacterial challenge, Sigma-Aldrich®. 
or equivalent volume of vehicle), heparinized blood was collected 3h after GBS injection, 
centrifuged (10,000g, 4°C, 10min), plated on agar overnight and CFUs counted the following 
day. For the survival experiments, mice were observed every 6h for up to 80h. In accordance 
with Home Office guidance, mice were humanely culled if they had a “sickness score” of 4 or 
3 for greater than 24h (Supplementary Table 2). 
   
Cytokine analysis  
Murine cytokine expression profiles were determined using Th1/Th2 10-plex FlowCytomix 
Mouse Kits (Bender MedSystems). Fluorescence was measured on a flow cytometer (BD 
FACSCanto II™, BD bioscience) and data analyzed using manufacturer’s software. The 
expression profile of a cytokine panel in human macrophage supernatants was measured using 
the MSD® Bio-Plex human cytokine assay (Merck, Sharp & Dohme Ltd.). Our assay was 
customized to detect/quantify IL-1, IL-6, IL-8, IL-10 and TNFα. Key cytokine changes were 
confirmed by dedicated ELISA (TNFα and IL10 - mouse eBioscience or human Duoset®, R&D 
systems). All samples were run in duplicate.  
 
Mouse blood analysis, macrophage isolation/culture  
Blood was collected by intracardiac puncture into heparin and centrifuged (10,000g, 4OC, 
10min). Plasma was analyzed for liver and renal function tests using the COBAS® INTEGRA 
400 plus multianalyser with appropriate diagnostic kits (Roche - Diagnostics) or stored at -
80°C. Peritoneal macrophages from healthy animals were isolated as described previously20 
and incubated with/without LPS (Salmonella Typhosa, 0.1μg/mL for 24h; Sigma-Aldrich®) in 
the presence of plasma (50μl) from naïve, sham, BDL or CCL4 mice in cell culture media 
(complete DMEM; Life Technologies™) to give a final concentration of 25% by volume. In 
other experiments plasma was added to cell culture, as above, from BDL mice given 
indomethacin (3mg.kg-1 po 6h prior to sampling); the cytochrome P450 inhibitor SKF525A 
(Enzo® Life Sciences; 50mg.kg-1 s.c. 1h prior to sampling); or the 12/15 lipoxygenase (LOX) 
inhibitor Bacalein (Sigma-Aldrich®; 100mg.kg-1 s.c. 90min prior to sampling). In experiments 
examining the effect of the DP1/EP1-3 receptor antagonist AH6809 (300μM; Sigma-
Aldrich®), this compound was dissolved in DMEM and added to macrophages 45min prior to 
addition of plasma.  Cell viability was ascertained with the calcein AM cell viability assay kit 
(Biotium, Inc) in accordance with manufacturer’s instructions. For heat inactivation, plasma 
was placed at 56°C in a water bath for 1h and samples stored overnight at 4°C and used for cell 
culture the following day. 
 
Immunohistochemistry 
For COX 1 and COX 2 expression, immunohistochemistry was carried out on formalin-fixed, 
wax-embedded mouse tissues using COX 1 polyclonal antibody (Cayman Chemical, catalogue 
number 160109) and COX-2 polyclonal antibody (Cayman Chemical, catalogue number 
160106) using rabbit anti-mouse as secondary. 
 
Randomisation 
Cages of animals (n=5/cage) were randomly allocation to surgical or chemical-induced liver 
injury. Thereafter, groups of mice were allocated to receive drug intervention, infectious 
stimuli or both. In addition, groups of liver disease mice and sham controls were chosen for 
plasma extraction for ex vivo bioassays, where appropriate. For human studies, randomisation 
was not possible as human monocyte-derive macrophages received plasma from either healthy 
volunteers or from liver disease patients. 
 
Blinding 
For all mouse and human cell culture and bacteria experiments and mouse survival 
experiments, the investigator was blinded to the sample source during both the experiment and 
analysis of the data.  
 
Statistical analysis  
For calculation of group sizes, from experiments with murine peritonitis, cellular profiles, 
inflammatory protein expression and lipid mediator production is extremely reproducible. We 
found with random allocation of animals to each group that intra-animal replicate variability is 
much less than inter-animal biological variability. An effect size of ~40% of parameter mean 
is considered biologically relevant. Using this and population statistics, to enable statistical 
determination at a P<0.05 in a primary ANOVA screen followed by post-hoc Bonferroni 
corrected T-test at 90% power, a group size of 5 animals is necessary with a maximum of 5 
groups per experiment. Applying this approach to humans using human cirrhotic plasma on 
humans cells with bacterial killing and TNFα as a readout, a minimum of n=10/group was 
required in order to discern significant changes in immune function. Statistical analysis was 
performed using GraphPad Prism 4 (GraphPad Software). For comparisons between multiple 
groups, 1-way ANOVA with repeated measures was performed followed by Bonferroni post-
test. Comparisons between 2 groups were made by 2-tailed (un)paired t test. Differences 
between time-response curves were assessed by 2-way ANOVA. Correlations between 
variables were calculated using linear regression with Pearson statistic. For data not normally 
distributed (clinical data presented in Table 1) the Mann-Whitney test was used. P < 0.05 was 
considered statistically significant. No data, either rodent or human, were excluded from 
analysis.  
 
 
Figure S1. PGF2α, 5- and 15-HETE are elevated in plasma of patients with Acute 
Decompensation (AD) when compared with healthy volunteers. (a-g)  Lipidomic LC/ESI-
MS/MS analysis of plasma from AD patients and healthy volunteers (n=8 healthy volunteers 
and 14 AD patients). Data are represented as mean ± SEM.  * P<0.05 t-test. 
 
Figure S2. Aside from PGE2 other plasma eicosanoids are not elevated in bile duct 
ligation (BDL) liver injury mice. (a-p) Lipidomic LC/ESI-MS/MS analysis of plasma lipids 
from naïve, sham and BDL mice (n=6-8 mice/group). Data are represented as mean ± SEM. 
 
Figure S3. The immunosuppressive properties of BDL liver injury mice plasma are 
mediated by PGE2. (a) IL-6 and (b) IL-10 release from LPS stimulated peritoneal 
macrophages from naive mice in the presence of healthy (naïve) or BDL mice plasma with or 
without prior administration of indomethacin, SKF525A or baicalein (n=6-8 mice/group).  (c) 
TNFα and (d) IL-10 release from LPS stimulated peritoneal macrophages from naive mice in 
the presence or absence of PGE2 at concentrations found in plasma of BDL or CCL4 mice 
(n=8-10 mice per group). (e) TNFα and (f) IL-10 release from from LPS stimulated 
peritoneal macrophages from naive mice in the presence of healthy (naïve) or BDL mice 
plasma with or without AH6809 (300μM) (n=6 mice/group). (g)TNFα, (h) IL6 and (i) IL-10 
release from LPS stimulated peritoneal macrophages from BDL mice in the presence of 
healthy (naïve) or BDL mice plasma (n=4 mice/group). Data are represented as mean ± SEM. 
* P<0.05 ** P<0.01 ***P<0.001, ANOVA or t-test where appropriate. 
 
Figure S4. Aside from PGD2 and PGE2, no other eicosanoid was elevated in plasma 
from CCL4 mice when compared to shams. (a-p) Lipidomic LC/ESI-MS/MS analysis of 
plasma from sham and CCL4 mice (n=6-8 mice/group). Data are represented as mean ± 
SEM. * P<0.05, t-test. 
 
Figure S5. PGE2 antagonism with AH6809 has a greater immune restorative effect on 
ADMIS (most immunosuppressive) compared with ADLIS (least immunosuppressed) 
plasma samples. (a-d) TNFα and IL-10 release from human monocyte-derived macrophages 
stimulated with LPS in the presence of plasma from AD patients, patients awaiting liver 
transplant sampled 24 weeks apart and healthy volunteers with and without AH6809; with 
cirrhosis patients grouped into into ADMIS and ADLIS. (e) LPS-stimulated human monocyte-
derived macrophages TNFα synthesis in the presence of healthy volunteer or AD plasma 
samples in patients administered 0.9% saline on days 1(400-600ml) & 3 (200-400ml) of 
admission with samples obtained during admission and at 10-20 or 30-60 days post discharge 
(n=10). Data are represented as mean ± SEM. * P<0.05 ** P<0.01 ***P<0.001, ANOVA. 
 
